Releases
CUE
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest Cue Biopharma (CUE) stock and general news. This information may help you make smarter investment decisions.
About CUE
Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.